Posted by Michael Wonder on 09 Jun 2021
Alzheimer’s drug is bonanza for Biogen, most likely at taxpayer expense
8 June 2021 - The FDA’s decision on Monday to approve a new Alzheimer’s medication over the fierce objections of its scientific advisers sets into motion one of the most controversial drug introductions in years.
For its manufacturer, Biogen, the new drug is poised to be a blockbuster. For just about everyone else, it is likely to further inflate high U.S. health care costs.
And that is despite the fact that there is not much evidence the drug actually works.
